Biomaterials are continually being designed that enable new methods for interacting dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug delivery to regenerative medicine. In this review, we explore some of the recent advances being made in regards to programming biomaterials for improved drug delivery, with a focus on cancer and infection. We begin by explaining several of the underlying concepts that are being used to design this new wave of drug delivery vehicles, followed by examining recent materials systems that are able to coordinate the temporal delivery of multiple therapeutics, dynamically respond to changing tissue environments, and reprogram their bioactivity over time.
HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell2011; 144: 646–74.
2.
CostertonJW. Bacterial biofilms: a common cause of persistent infections. Science1999; 284: 1318–22.
3.
LoebLALoebKRAndersonJP. Multiple mutations and cancer. Proc Natl Acad Sci U S A2003; 100: 776–81.
4.
StewartPSCostertonJW. Antibiotic resistance of bacteria in biofilms. Lancet2001; 358: 135–8.
5.
ZhongHDe MarzoAMLaughnerELimMHiltonDAZagzagDBuechlerPIsaacsWBSemenzaGLSimonsJW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Canc Res1999; 59: 5830–5.
6.
SchuetzPChrist-CrainMMüllerB. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care2007; 13: 578–85.
7.
SanvicensNMarcoMP. Multifunctional nanoparticles – properties and prospects for their use in human medicine. Trends Biotechnol2008; 26: 425–33.
8.
DavisMEChenZGShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov2008; 7: 771–82.
9.
WangAZLangerRFarokhzadOC. Nanoparticle delivery of cancer drugs. Annu Rev Med2012; 63: 185–98.
10.
Al-LazikaniBBanerjiUWorkmanP. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol2012; 30: 679–92.
11.
OlivaNUntermanSZhangYCondeJSongHSArtziN. Personalizing biomaterials for precision nanomedicine considering the local tissue microenvironment. Adv Healthc Mater2015; 4: 1584–99.
12.
PacardoDBLiglerFSGuZ. Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale2015; 7: 3381–91.
13.
ZazoHColinoCILanaoJM. Current applications of nanoparticles in infectious diseases. J Contr Release2016; 224: 86–102.
14.
WohlBMEngbersenJFJ. Responsive layer-by-layer materials for drug delivery. J Contr Release2012; 158: 2–14.
15.
DeMGhoshPSRotelloVM. Applications of nanoparticles in biology. Adv Mater2008; 20: 4225–41.
16.
BlancoEShenHFerrariM. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol2015; 33: 941–51.
17.
AllenTMCullisPR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev2013; 65: 36–48.
18.
CostaRRAlatorre-MedaMManoJF. Drug nano-reservoirs synthesized using layer-by-layer technologies. Biotechnol Adv2015; 33: 1310–26.
19.
KesharwaniPJainKJainNK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci2014; 39: 268–307.
20.
AlkilanyAMThompsonLBBoulosSPSiscoPNMurphyCJ. Gold nanorods: their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Deliv Rev2012; 64: 190–9.
21.
HoffmanAS. Hydrogels for biomedical applications. Adv Drug Deliv Rev2012; 64: 18–23.
22.
MealyJERodellCBBurdickJA. Sustained small molecule delivery from injectable hyaluronic acid hydrogels through host-guest mediated retention. J Mater Chem B Mater Biol Med2015; 3: 8010–9.
23.
HoareTRKohaneDS. Hydrogels in drug delivery: progress and challenges. Polymer2008; 49: 1993–2007.
24.
StrongLEDahotreSNWestJL. Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery. J Contr Release2014; 178: 63–8.
25.
BrudnoYDesaiRMKweeBJJoshiNSAizenbergMMooneyDJ. In vivo targeting through click chemistry. ChemMedChem2015; 10: 617–20.
26.
MurphyNPLampeKJ. Mimicking biological phenomena in hydrogel-based biomaterials to promote dynamic cellular responses. J Mater Chem B2015; 3: 7867–80.
27.
PattersonJHubbellJA. Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials2010; 31: 7836–45.
28.
O’BrienFJHarleyBAYannasIVGibsonLJ. The effect of pore size on cell adhesion in collagen-GAG scaffolds. Biomaterials2005; 26: 433–41.
29.
RapeADZibinskyMMurthyNKumarS. A synthetic hydrogel for the high-throughput study of cell-ECM interactions. Nat Commun2015; 6: 8129–8129.
30.
KimJLiWAChoiYLewinSAVerbekeCSDranoffGMooneyDJ. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol2015; 33: 64–72.
BaskinJMPrescherJALaughlinSTAgardNJChangPVMillerIALoACodelliJABertozziCR. Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci U S A2007; 104: 16793–7.
38.
ZhaoWSchaferSChoiJYamanakaYJLombardiMLBoseSCarlsonALPhillipsJATeoWDroujinineIACuiCHJainRKLammerdingJLoveJCLinCPSarkarDKarnikRKarpJM. Cell-surface sensors for real-time probing of cellular environments. Nat Nanotechnol2011; 6: 524–31.
39.
BöhmeDBeck-SickingerAG. Drug delivery and release systems for targeted tumor therapy. J Pept Sci2015; 21: 186–200.
40.
AlleySCOkeleyNMSenterPD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol2010; 14: 529–37.
41.
TyagiSKramerFR. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol1996; 14: 303–8.
42.
ZhengJYangRShiMWuCFangXLiYLiJTanW. Rationally designed molecular beacons for bioanalytical and biomedical applications. Chem Soc Rev2015; 44: 3036–55.
43.
MarrasSAE. Selection of fluorophore and quencher pairs for fluorescent nucleic acid hybridization probes. Meth Mol Biol2006; 335: 3–16.
44.
CondeJOlivaNArtziN. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc Natl Acad Sci U S A2015; 112: E1278–87.
LiuZDuanJ-HSongY-MMaJWangF-DLuXYangX-D. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med2012; 10: 148–148.
TuerkCGoldL. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science1990; 249: 505–10.
49.
EllingtonADSzostakJW. In vitro selection of RNA molecules that bind specific ligands. Nature1990; 346: 818–22.
50.
KeefeADPaiSEllingtonA. Aptamers as therapeutics. Nat Rev Drug Discov2010; 9: 537–50.
51.
BraaschDACoreyDR. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol2001; 8: 1–7.
52.
RayANordenB. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J2000; 14: 1041–60.
53.
SuranaSShenoyARKrishnanY. Designing DNA nanodevices for compatibility with the immune system of higher organisms. Nat Nanotechnol2015; 10: 741–7.
54.
DeVitaVTChuE. A history of cancer chemotherapy. Canc Res2008; 68: 8643–53.
55.
SenguptaSEavaroneDCapilaIZhaoGWatsonNKiziltepeTSasisekharanR. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature2005; 436: 568–72.
56.
LeeMJYeASGardinoAKHeijinkAMSorgerPKMacBeathGYaffeMB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell2012; 149: 780–94.
57.
MortonSWLeeMJDengZJDreadenECSiouveEShopsowitzKEShahNJYaffeMBHammondPT. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal2014; 7: ra44–ra44.
58.
ParkerNTurkMJWestrickELewisJDLowPSLeamonCP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem2005; 338: 284–93.
59.
DreadenECKongYWMortonSWCorreaSChoiKYShopsowitzKERenggliKDrapkinRYaffeMBHammondPT. Tumor-targeted synergistic blockade of MAPK and PI3K from a layer-by-layer nanoparticle. Clin Canc Res2015; 21: 4410–9.
60.
Von MaltzahnGParkJ-HLinKYSinghNSchwöppeCMestersRBerdelWERuoslahtiESailorMJBhatiaSN. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater2011; 10: 545–52.
61.
JohnCWYAbatangeloG. Functions of hyaluronan in wound repair. Wound Repair Regen1999; 7: 79–89.
JiangTMoRBellottiAZhouJGuZ. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv Funct Mater2014; 24: 2295–304.
64.
SunWJiangTLuYReiffMMoRGuZ. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J Am Chem Soc2014; 136: 14722–5.
65.
CondeJBaoCTanYCuiDEdelmanERAzevedoHSByrneHJArtziNTianF. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater2015; 25: 4183–94.
66.
SegoviaNPontMOlivaNRamosVBorrósSArtziN. Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer. Adv Healthc Mater2015; 4: 271–80.
67.
Gilboa-GeffenAHamarPLeMTNWheelerLATrifonovaRPetroccaFWittrupALiebermanJ. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Canc Ther2015; 14: 2279–91.
68.
DassieJPLiuX-YThomasGSWhitakerRMThielKWStockdaleKRMeyerholzDKMcCaffreyAPMcNamaraJOGiangrandePH. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol2009; 27: 839–49.
69.
LaiW-YWangW-YChangY-CChangC-JYangP-CPeckK. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials2014; 35: 2905–14.
70.
NeffCPZhouJRemlingLKuruvillaJZhangJLiHSmithDDSwiderskiPRossiJJAkkinaR. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med2011; 3: 66ra6–66ra6.
71.
ZhouJLiHLiSZaiaJRossiJJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther2008; 16: 1481–9.
72.
WheelerLATrifonovaRVrbanacVBasarEMcKernanSXuZSeungEDeruazMDudekTEinarssonJIYangLAllenTMLusterADTagerAMDykxhoornDMLiebermanJ. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest2011; 121: 2401–12.
73.
McNamaraJOAndrechekERWangYVilesKDRempelREGilboaESullengerBAGiangrandePH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol2006; 24: 1005–15.
74.
ZhangZLiSChenNYangCWangY. Programmable display of DNA-protein chimeras for controlling cell-hydrogel interactions via reversible intermolecular hybridization. Biomacromolecules2013; 14: 1174–80.
75.
PippigDABaumannFStrackharnMAschenbrennerDGaubHE. Protein-DNA chimeras for nano assembly. ACS Nano2014; 8: 6551–5.
76.
BrudnoYSilvaEAKearneyCJLewinSAMillerAMartinickKDAizenbergMMooneyDJ. Refilling drug delivery depots through the blood. Proc Natl Acad Sci U S A2014; 111: 12722–7.
77.
CouvreurP. Drug delivery: replenishing reservoirs in vivo. Nat Nanotechnol2014; 9: 874–5.
78.
HawkeyPMJonesAM. The changing epidemiology of resistance. J Antimicrob Chemother2009; 64: i3–10.
79.
NikaidoH. Multidrug resistance in bacteria. Annu Rev Biochem2009; 78: 119–46.
80.
JakobssonHEJernbergCAnderssonAFSjölund-KarlssonMJanssonJKEngstrandL. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One2010; 5: e9836–e9836.
81.
SommerMOADantasGChurchGM. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science2009; 325: 1128–31.
82.
ZhangXSoontornworajitBZhangZChenNWangY. Enhanced loading and controlled release of antibiotics using nucleic acids as an antibiotic-binding effector in hydrogels. Biomacromolecules2012; 13: 2202–10.
83.
KavrukMCelikbicakOOzalpVCBorsaBAHernandezFJBayramogluGSalihBAricaMY. Antibiotic loaded nanocapsules functionalized with aptamer gates for targeted destruction of pathogens. Chem Commun2015; 51: 8492–5.
84.
HernandezFJHernandezLIKavrukMArıcaYMBayramoğluGBorsaBAÖktemHASchäferTÖzalpVC. NanoKeepers: stimuli responsive nanocapsules for programmed specific targeting and drug delivery. Chem Commun2014; 50: 9489–92.
85.
SundaramPWowerJByrneME. A nanoscale drug delivery carrier using nucleic acid aptamers for extended release of therapeutic. Nanomedicine2012; 8: 1143–51.
BlumJHDoveSLHochschildAMekalanosJJ. Isolation of peptide aptamers that inhibit intracellular processes. Proc Natl Acad Sci U S A2000; 97: 2241–6.
88.
ChenFZhouJLuoFMohammedA-BZhangX-L. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Biophys Res Commun2007; 357: 743–8.
89.
SuchGKJohnstonAPRLiangKCarusoF. Synthesis and functionalization of nanoengineered materials using click chemistry. Prog Polym Sci2012; 37: 985–1003.
90.
PrescherJADubeDHBertozziCR. Chemical remodelling of cell surfaces in living animals. Nature2004; 430: 873–7.
91.
SaxonELuchanskySJHangHCYuCLeeSCBertozziCR. Investigating cellular metabolism of synthetic azidosugars with the staudinger ligation. J Am Chem Soc2002; 124: 14893–902.
92.
SaxonEBertozziC. Cell surface engineering by a modified staudinger reaction. Science2000; 287: 2007–10.
93.
ChangPVPrescherJASlettenEMBaskinJMMillerIAAgardNJLoABertozziCR. Copper-free click chemistry in living animals. Proc Natl Acad Sci U S A2010; 107: 1821–6.
94.
KooHLeeSNaJHKimSHHahnSKChoiKKwonICJeongSYKimK. Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed Engl2012; 51: 11836–40.
95.
LeeSKooHNaJHHanSJMinHSLeeSJKimSHYunSHJeongSYKwonICChoiKKimK. Chemical tumor-targeting of nanoparticles based on metabolic glycoengineering and click chemistry. ACS Nano2014; 8: 2048–63.
96.
GanewattaMSMillerKPSingletonSPMehrpouya-BahramiPChenYPYanYNagarkattiMNagarkattiPDechoAWTangC. Antibacterial and biofilm-disrupting coatings from resin acid-derived materials. Biomacromolecules2015; 16: 3336–44.
97.
ShakibaAJamisonACLeeTR. Poly(L-lysine) interfaces via dual click reactions on surface-bound custom-designed dithiol adsorbates. Langmuir2015; 31: 6154–63.
98.
KimJMooneyDJ. In vivo modulation of dendritic cells by engineered materials: towards new cancer vaccines. Nano Today2011; 6: 466–77.
99.
AliOAHuebschNCaoLDranoffGMooneyDJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater2009; 8: 151–8.
100.
LeeTTGarcíaJRPaezJISinghAPhelpsEAWeisSShafiqZShekaranADel CampoAGarcíaAJ. Light-triggered in vivo activation of adhesive peptides regulates cell adhesion, inflammation and vascularization of biomaterials. Nat Mater2015; 14: 352–60.
101.
WirknerMWeisSSan MiguelVÁlvarezMGropeanuRASaliernoMSartorisAUngerREKirkpatrickCJdel CampoA. Photoactivatable caged cyclic RGD peptide for triggering integrin binding and cell adhesion to surfaces. Chembiochem2011; 12: 2623–9.
102.
MaedaHNakamuraHFangJ. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev2013; 65: 71–9.
103.
SchaalJLLiXMastriaEBhattacharyyaJZalutskyMRChilkotiALiuW. Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. J Contr Release2016; 228: 58–66.
104.
FakhariASubramonyJA. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. J Contr Release2015; 220: 465–75.
105.
TangWBeckerML. ‘Click’ reactions: a versatile toolbox for the synthesis of peptide-conjugates. Chem Soc Rev2014; 43: 7013–39.
106.
LutolfMP. Integration column: artificial ECM: expanding the cell biology toolbox in 3D. Integr Biol2009; 1: 235–41.
